A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer

Seminars in Oncology

Volumn 28, Issue 4 SUPPL. 15, 2001, Pages 62-66

  Figg, William D ^a   Arlen, Phil ^a   Gulley, James ^a   Fernandez, Patricia ^a   Noone, Marianne ^a   Fedenko, Kathy ^a   Hamilton, Mike ^a   Parker, Catherine ^a   Kruger, Erwin A ^a   Pluda, James ^a   Dahut, William L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2,6 DIOXO 3 PIPERIDINYL)PHTHALIMIDINE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; DOCETAXEL; PROSTATE SPECIFIC ANTIGEN; THALIDOMIDE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; FATIGUE; HUMAN; HYPERGLYCEMIA; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MALE GENITAL TRACT CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT OUTCOME;

EID: 0034795178     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2001.26904     Document Type: Article

References (40)

1. Cancer statistics, 2001
2. Management of hormone-sensitive metastatic prostate cancer. Update on hormonal therapy
3. Optimal hormonal therapy for advanced prostatic carcinoma
4. Drug development in prostate cancer
5. Treatment approaches for metastatic cancer of the prostate based on recent molecular evidence
6. Chemotherapy for prostatic carcinoma
7. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer
8. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the Cancer and Leukemia Group B 9182 study
9. Preclinical in vivo activity of docetaxel-containing combinations
10. Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines
11. Bcl2 is the guardian of microtubule integrity
12. Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer
13. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer
14. Docetaxel (Taxotere) in hormone-refractory prostate cancer
15. Docetaxel (Taxotere) as monoherapy in the treatment of hormone-refractory prostate cancer: Preliminary results
16. Thalidomide: A prodrug inhibits angiogenesis
17. Thalidomide
18. Thalidomide and congenital abnormalities
19. Thalidomide and congenital abnormalities
20. Thalidomide is an inhibitor of angiogenesis
21. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent
22. Activity of thalidomide in AIDS-related Kaposi's sarcoma
23. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas
24. Thalidomide for resistant and relapsing myeloma
25. Antitumor activity of thalidomide in refractory multiple myeloma
26. Randomized phase II study of thalidomide in androgen-independent prostate cancer (AIPC)
27. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer
28. Eligibility and response guidelines for phase II clinical trials in androgenindependent prostate cancer: Recommendations from the Prostate-specific Antigen Working Group
29. Taxanes in hormone-refractory prostate cancer
30. Current management of hormone refractory prostate cancer
31. Tumour angiogenesis in prostatic carcinoma with and without bone marrow metastasis: A morphometric study
32. Topography of neovascularity in human prostate carcinoma
33. Tumour angiogenesis in latent prostatic carcinoma
34. Microvessel density in prostate cancer: Prognostic and therapeutic utility
35. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma
36. Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate
37. Vascular density is a predictor of cancer-specific survival in prostatic carcinoma
38. Significance of tumor angiogenesis in clinically localized prostate carcinoma treated with external beam radiotherapy
39. Microvessel density in prostate cancer: Lack of correlation with tumor grade, pathologic stage, and clinical outcome
40. Pharmacokinetics of thalidomide in an eldely prostate cancer population